Year All2026202520242023202220212020201920182017201620152014 Oct 28, 2025 Soleno Therapeutics to Participate in Upcoming November Conferences Oct 21, 2025 Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET Oct 13, 2025 Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors Aug 27, 2025 Soleno Therapeutics to Participate in Upcoming September Conferences Aug 06, 2025 Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results Jul 28, 2025 Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET Jul 10, 2025 Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock Jul 10, 2025 Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock Jul 10, 2025 Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 Jul 01, 2025 Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025
Oct 21, 2025 Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
Oct 13, 2025 Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
Aug 06, 2025 Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
Jul 28, 2025 Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
Jul 10, 2025 Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
Jul 01, 2025 Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025